Windtree Therapeutics Announces Virtual Investor Day Presentation on October 1 at 3pm ET
Windtree Therapeutics (NasdaqCM: WINT) has announced a virtual Investor Day Presentation scheduled for October 1 at 3pm ET. The event will showcase new positive topline results from the Phase 2b SEISMiC Extension Study of istaroxime in early cardiogenic shock. Windtree will discuss the istaroxime cardiogenic shock opportunity, company strategy, and planned near-term milestones.
Joining the management team will be Dr. Alexandre Mebazaa, a global expert in cardiogenic shock and heart failure. The presentation will be followed by a Q&A session. Istaroxime, Windtree's novel first-in-class therapy, is designed to improve heart function and blood pressure while maintaining or improving renal function. It has shown positive results in four Phase 2 trials for acute heart failure and early cardiogenic shock.
Windtree Therapeutics (NasdaqCM: WINT) ha annunciato una presentazione virtuale per gli investitori prevista per il 1 ottobre alle 15:00 ET. L'evento presenterà nuovi risultati positivi preliminari dallo Studio di Estensione di Fase 2b SEISMiC dell'istaroxime in caso di shock cardiogeno precoce. Windtree discuterà dell'opportunità dell'istaroxime per il trattamento dello shock cardiogeno, della strategia aziendale e delle milestone a breve termine programmate.
Insieme al team di gestione ci sarà il Dr. Alexandre Mebazaa, esperto a livello globale in shock cardiogeno e insufficienza cardiaca. La presentazione sarà seguita da una sessione di domande e risposte. L'istaroxime, la terapia innovativa di prima classe di Windtree, è progettata per migliorare la funzione cardiaca e la pressione sanguigna mantenendo o migliorando la funzione renale. Ha mostrato risultati positivi in quattro studi di Fase 2 per insufficienza cardiaca acuta e shock cardiogeno precoce.
Windtree Therapeutics (NasdaqCM: WINT) ha anunciado una presentación virtual para inversores programada para el 1 de octubre a las 3 p.m. ET. El evento mostrará nuevos resultados positivos preliminares del Estudio de Extensión de Fase 2b SEISMiC del istaroxime en caso de shock cardiogénico temprano. Windtree discutirá la oportunidad del istaroxime para el shock cardiogénico, la estrategia de la empresa y los hitos a corto plazo planificados.
Acompañando al equipo directivo estará el Dr. Alexandre Mebazaa, un experto global en shock cardiogénico e insuficiencia cardíaca. La presentación será seguida de una sesión de preguntas y respuestas. El istaroxime, la novedosa terapia de primera clase de Windtree, está diseñada para mejorar la función cardíaca y la presión arterial mientras mantiene o mejora la función renal. Ha mostrado resultados positivos en cuatro ensayos de Fase 2 para insuficiencia cardíaca aguda y shock cardiogénico temprano.
Windtree Therapeutics (NasdaqCM: WINT)가 10월 1일 오후 3시(동부 표준시)에 예정된 가상 투자자 발표를 발표했습니다. 이 이벤트에서는 조기 심장이상 쇼크에 대한 2b단계 SEISMiC 연장 연구의 새로운 긍정적인 초기 결과가 소개됩니다. Windtree는 이스타록심의 심장이상 쇼크 기회, 회사 전략 및 예정된 단기 이정표에 대해 논의할 것입니다.
경영진 팀에는 알렉상드르 메바자 박사, 심장이상 쇼크와 심부전의 세계적 전문가가 함께할 것입니다. 발표 후에는 질의응답 세션이 이어질 예정입니다. 이스타록심은 Windtree의 독창적인 1세대 치료제로, 심장 기능 및 혈압을 개선하면서 신장 기능을 유지하거나 개선하도록 설계되었습니다. 이스타록심은 4건의 2단계 시험에서 급성 심부전 및 조기 심장이상 쇼크에 대해 긍정적인 결과를 보여주었습니다.
Windtree Therapeutics (NasdaqCM: WINT) a annoncé une présentation virtuelle pour les investisseurs prévue le 1er octobre à 15h00 ET. L'événement mettra en avant de nouveaux résultats positifs préliminaires de l'étude d'extension de Phase 2b SEISMiC sur l'istaroxime dans le cas d'un choc cardiogène précoce. Windtree discutera de l'opportunité de l'istaroxime pour le choc cardiogène, de la stratégie de l'entreprise et des jalons à court terme prévus.
Le comité de direction sera rejoint par Dr. Alexandre Mebazaa, un expert mondial en choc cardiogène et en insufisance cardiaque. La présentation sera suivie d'une session de questions-réponses. L'istaroxime, la thérapie innovante de première classe de Windtree, est conçue pour améliorer la fonction cardiaque et la pression artérielle tout en maintenant ou en améliorant la fonction rénale. Elle a montré des résultats positifs dans quatre essais de Phase 2 pour insufisance cardiaque aiguë et choc cardiogène précoce.
Windtree Therapeutics (NasdaqCM: WINT) hat eine virtuelle Investorenpräsentation für den 1. Oktober um 15:00 Uhr ET angekündigt. Die Veranstaltung wird neue positive vorläufige Ergebnisse aus der Phase 2b SEISMiC Erweiterungsstudie zu Istaroxim bei frühem kardiogenem Schock präsentieren. Windtree wird die Istaroxim-Möglichkeit bei kardiogenem Schock, die Unternehmensstrategie und die geplanten kurzfristigen Meilensteine diskutieren.
Das Managementteam wird von Dr. Alexandre Mebazaa, einem globalen Experten für kardiogenen Schock und Herzinsuffizienz, begleitet. Die Präsentation wird von einer Frage-und-Antwort-Runde gefolgt. Istaroxim, die neuartige Therapie der ersten Klasse von Windtree, ist darauf ausgelegt, die Herzfunktion und den Blutdruck zu verbessern, während die Nierenfunktion aufrechterhalten oder verbessert wird. Es hat positive Ergebnisse in vier Phase-2-Studien zu akuter Herzinsuffizienz und frühem kardiogenem Schock gezeigt.
- Positive topline results from Phase 2b SEISMiC Extension Study of istaroxime in early cardiogenic shock
- Istaroxime has shown positive results in four Phase 2 trials for acute heart failure and early cardiogenic shock
- Participation of a global expert in cardiogenic shock and heart failure in the Investor Day Presentation
- None.
New Istaroxime Phase 2b clinical results to be presented by Windtree and top cardiology expert
Review of cardiogenic shock and other programs, including Windtree’s strategy and planned near-term milestones
WARRINGTON, Pa., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced it will hold a virtual Investor Day Presentation on October 1 at 3pm ET.
The Investor Day will present the new positive topline results of the Phase 2b SEISMiC Extension Study of istaroxime in early cardiogenic shock, istaroxime cardiogenic shock opportunity and the Company’s strategy going forward, including planned near-term milestones. Joining the management team will be Alexandre Mebazaa, MD, PhD, Professor at the Hospital Lariboisière, Paris, France, who is a global expert in cardiogenic shock and heart failure. There will be a Q&A session following the presentation.
The Investor Day will be held on October 1 at 3pm ET on Zoom and investors can register at this address: https://lifescievents.com/event/windtreetx/.
Early cardiogenic shock is characterized by low blood pressure and the patient is at risk of developing inadequate blood flow to vital organs. Istaroxime is a novel first-in-class therapy that is designed to improve systolic contraction and diastolic relaxation of the heart while also increasing blood pressure and maintaining or improving renal function. It has been studied in four positive Phase 2 trials enrolling patients with acute heart failure and early cardiogenic shock.
About Istaroxime
Istaroxime is a first-in-class dual-mechanism therapy designed to improve both systolic and diastolic cardiac function. Istaroxime is a positive inotropic agent that increases myocardial contractility through inhibition of Na+/K+- ATPase with a complimentary mechanism that facilitates myocardial relaxation through activation of the SERCA2a calcium pump on the sarcoplasmic reticulum enhancing calcium reuptake from the cytoplasm. Data from multiple Phase 2 studies in patients with early cardiogenic shock or acute decompensated heart failure demonstrate that istaroxime infused intravenously significantly improves cardiac function and blood pressure without increasing heart rate or the incidence of cardiac rhythm disturbances.
About Windtree Therapeutics, Inc.
Windtree Therapeutics, Inc. is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Windtree’s portfolio of product candidates includes istaroxime, a Phase 2 candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. Windtree also has a licensing business model with partnership out-licenses currently in place.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations. Examples of such risks and uncertainties include, among other things: the Company’s ability to secure significant additional capital as and when needed; the Company’s ability to achieve the intended benefits of the aPKCi asset acquisition with Varian Biopharmaceuticals, Inc.; the Company’s risks and uncertainties associated with the success and advancement of the clinical development programs for istaroxime and the Company’s other product candidates, including preclinical oncology candidates; the Company’s ability to access the debt or equity markets; the Company’s ability to manage costs and execute on its operational and budget plans; the results, cost and timing of the Company’s clinical development programs, including any delays to such clinical trials relating to enrollment or site initiation; risks related to technology transfers to contract manufacturers and manufacturing development activities; delays encountered by the Company, contract manufacturers or suppliers in manufacturing drug products, drug substances, and other materials on a timely basis and in sufficient amounts; risks relating to rigorous regulatory requirements, including that: (i) the U.S. Food and Drug Administration or other regulatory authorities may not agree with the Company on matters raised during regulatory reviews, may require significant additional activities, or may not accept or may withhold or delay consideration of applications, or may not approve or may limit approval of the Company’s product candidates, and (ii) changes in the national or international political and regulatory environment may make it more difficult to gain regulatory approvals and risks related to the Company’s efforts to maintain and protect the patents and licenses related to its product candidates; risks that the Company may never realize the value of its intangible assets and have to incur future impairment charges; risks related to the size and growth potential of the markets for the Company’s product candidates, and the Company’s ability to service those markets; the Company’s ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of the Company’s product candidates, if approved; the economic and social consequences of the COVID-19 pandemic and the impacts of political unrest, including as a result of geopolitical tension, including the conflict between Russia and Ukraine, the People’s Republic of China and the Republic of China (Taiwan), and the evolving events in Israel and Gaza, and any sanctions, export controls or other restrictive actions that may be imposed by the United States and/or other countries which could have an adverse impact on the Company’s operations, including through disruption in supply chain or access to potential international clinical trial sites, and through disruption, instability and volatility in the global markets, which could have an adverse impact on the Company’s ability to access the capital markets. These and other risks are described in the Company’s periodic reports, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Contact Information:
Eric Curtis
ecurtis@windtreetx.com
FAQ
When is Windtree Therapeutics (WINT) holding its virtual Investor Day Presentation?
What will be presented during Windtree Therapeutics' (WINT) Investor Day?
How many Phase 2 trials has Windtree Therapeutics' (WINT) istaroxime completed?
What is the primary focus of Windtree Therapeutics' (WINT) istaroxime therapy?
